Key Highlights
- Q1 net income reached $745 million, showing growth from $654 million in the prior-year period
- Quarterly revenue totaled $6.02 billion, falling below Wall Street’s $6.35 billion projection
- Adjusted earnings per share of $2.60 came in under the Street consensus of $2.98
- A March cybersecurity incident linked to Iranian hackers created operational challenges and affected financial performance
- Shares declined approximately 2% to $308.75 in extended trading; company reaffirmed annual forecasts
The medical technology giant delivered a first-quarter performance that exceeded prior-year profitability but failed to meet analyst expectations on both revenue and earnings metrics. The quarter’s performance was significantly affected by a March cybersecurity breach.
Shares of SYK declined roughly 2% in post-market trading, settling at $308.75 after the earnings announcement.
The medical device manufacturer reported net earnings of $745 million, translating to $1.93 per diluted share, compared with $654 million, or $1.69 per share, during the same quarter last year. When adjusted for one-time items, earnings per share stood at $2.60, below the analyst consensus of $2.98.
Quarterly sales registered at $6.02 billion for the three months concluding March 31. While this represented a 2.6% year-over-year advancement, it substantially missed the Street’s $6.35 billion forecast.
Security Breach Impacted Operations
During March, a hacking collective known as Handala, reportedly connected to Iran, took credit for a damaging cyberattack targeting Stryker’s infrastructure. The breach generated extensive operational disruptions affecting the company’s Microsoft-based systems and purportedly postponed certain surgical procedures.
Multiple employees and contract workers shared on social platforms that the hacking group’s emblem displayed on their computer login interfaces, though Reuters could not independently confirm these accounts.
Stryker had previously indicated in early April that the security incident would negatively affect first-quarter financial results. Thursday’s earnings report validated that assessment.
According to Wall Street Journal coverage at the time, the attackers stated their actions were motivated by retaliatory measures related to heightened tensions between the United States and Iran.
Divisional Performance Varied
Stryker’s largest division, MedSurg and Neurotechnology, registered a 5% sales gain to $3.21 billion. However, this figure trailed analyst projections of $3.83 billion.
The Orthopaedics division delivered comparatively stronger results. Revenue climbed 6.3% to $2.81 billion, surpassing analyst expectations of $2.51 billion.
Weaker market demand for implantable devices and equipment utilized in advanced surgical procedures — particularly spinal interventions and orthopedic operations — pressured overall performance metrics.
Stryker faces direct competition from Zimmer Biomet (ZBH) and Johnson & Johnson (JNJ) throughout the orthopedics marketplace, spanning categories including hip and knee reconstruction, trauma care, and sports medicine solutions.
Notwithstanding the quarter’s performance gaps, Stryker maintained its full-year financial projections. Management confirmed its outlook for adjusted annual earnings per share between $14.90 and $15.10.
The unchanged forecast suggests leadership believes the cybersecurity incident’s financial consequences are limited to the first quarter and will not materially impact full-year results.
With first-quarter adjusted EPS of $2.60 against full-year guidance of $14.90–$15.10 per share, the company anticipates accelerated earnings momentum throughout the final nine months.
Stryker confirmed its full-year adjusted earnings per share guidance of $14.90 to $15.10 per share remains intact.
